Eric Ross Professor

Office: Mrb 343

Phone: (970) 491-0688

Education

  • Ph.D., Mayo Graduate School

About

Numerous diseases including Parkinson's disease, Alzheimer's disease, late-onset diabetes, and the transmissible spongiform encephalopathies are associated with the formation of ordered protein aggregates, called amyloid fibrils. Despite considerable study, relatively little is known about the forces that drive amyloid aggregation. The major focus of my lab is defining how the amino acid sequence of a protein affects its propensity to form amyloid aggregates. 

We are using yeast prions as a model to address this question.  A prion is an infectious protein.  In yeast, a number of different prions have been identified, each involving the conversion of proteins from a soluble form into an insoluble amyloid form.  The rapid growth rate and ease of genetic manipulation of yeast make yeast prions a powerful model system for studying the causes and consequences of amyloid aggregation.

All but one of the yeast prion proteins contains a region that is enriched in the amino acids glutamine and asparagine.  Such glutamine/asparagine-rich regions are common in both the yeast and human genome, but predicting whether a given glutamine/asparagine-rich protein will form amyloid aggregates has proven difficult.  We recently developed a Prion Aggregation Prediction Algorithm (PAPA) that for the first time allows accurate prediction of the aggregation propensity of glutamine/asparagine-rich proteins (this algorithm can be found at http://combi.cs.colostate.edu/supplements/papa/). 

Remarkably, when PAPA is used to scan the human genome, four of the highest scoring proteins are ones that have recently been linked to various degenerative diseases, including ALS and certain forms of dementia.  We are currently examining some of the other high-scoring proteins, as well as working to refine the prediction accuracy of PAPA.

Additional interests include using yeast prions to examine the cellular response to amyloid, to identify potential therapeutic targets for the treatment of amyloid diseases and to examine why of all of the amyloid diseases, only a small subset are infectious.

Publications